CD274 and non-small cell lung carcinoma: In addition to the traditional treatments for NSCLC, immune checkpoint inhibitors (ICIs), including therapeutic antibodies to programmed cell death protein 1 (PD-1) or programmed cell death ligand-1 (PD-L1), display therapeutic breakthroughs in NSCLC, but the objective response rate (ORR) is not high [1].